Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs TG Therapeutics Inc — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $117.32, while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). Which is the better fit depends on your goals.
| QQQE | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $122.72 | $59.06 |
52-Week Low | $96.06 | $26.39 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE trades at $116.70, down 0.09% on the day, with a mixed technical signal showing a bullish overall trend but bearish moving averages. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to cap-weighted peers. Recent news highlights its appeal as a diversified alternative amid high market concentration, with SpaceX's upcoming Nasdaq-100 inclusion potentially driving passive inflows.
The outlook for QQQE is positive due to its defensive structure and uncorrelated performance, though technical indicators suggest near-term consolidation. Key risks include market volatility and reliance on growth stocks. Analyst sentiment is constructive, emphasizing its role in balanced Nasdaq exposure.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
